Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

PHASE3CompletedINTERVENTIONAL
Enrollment

582

Participants

Timeline

Start Date

May 14, 2009

Primary Completion Date

November 21, 2012

Study Completion Date

November 21, 2012

Conditions
Neisseria MeningitidisHaemophilus Influenzae Type b
Interventions
BIOLOGICAL

MenitorixTM

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

BIOLOGICAL

Pneumococcal conjugate vaccine GSK1024850A

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

BIOLOGICAL

PrevenarTM

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

BIOLOGICAL

MeningitecTM

Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

BIOLOGICAL

NeisVac-CTM

Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

BIOLOGICAL

InfanrixTM hexa

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

BIOLOGICAL

InfanrixTM penta

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

BIOLOGICAL

InfanrixTM IPV/Hib

Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study

BIOLOGICAL

InfanrixTM IPV

Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study

Trial Locations (28)

13355

GSK Investigational Site, Berlin

14197

GSK Investigational Site, Berlin

28040

GSK Investigational Site, Madrid

28935

GSK Investigational Site, Móstoles/Madrid

32457

GSK Investigational Site, Porta Westfalica

32479

GSK Investigational Site, Hille

32584

GSK Investigational Site, Löhne

48163

GSK Investigational Site, Münster

54290

GSK Investigational Site, Trier

67227

GSK Investigational Site, Frankenthal

68163

GSK Investigational Site, Mannheim

71720

GSK Investigational Site, Oberstenfeld

74523

GSK Investigational Site, Schwäbisch Hall

75015

GSK Investigational Site, Bretten

76189

GSK Investigational Site, Karlsruhe

77694

GSK Investigational Site, Kehl

77955

GSK Investigational Site, Ettenheim

81675

GSK Investigational Site, Munich

81735

GSK Investigational Site, Munich

86720

GSK Investigational Site, Nördlingen

88069

GSK Investigational Site, Tettnang

88348

GSK Investigational Site, Bad Saulgau

99425

GSK Investigational Site, Weimar

04720

GSK Investigational Site, Döbeln

07356

GSK Investigational Site, Bad Lobenstein

39-200

GSK Investigational Site, Dębica

Unknown

GSK Investigational Site, Krakow

41-103

GSK Investigational Site, Siemianowice Śląskie

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY